News

Biogen announced that aducanumab, its investigational treatment for early Alzheimer’s disease (AD), was accepted into the European Medicines Agency’s (EMA) Priority Medicines (PRIME) program. PRIME aims to bring treatments to patients faster by enhancing the EMA’s support for the...

Expands scope of certification to include additional Otsuka Group products, reflecting the company’s improved resiliency and continuous operational capability during unexpected events. Otsuka Holdings Co Ltd is pleased to announce that its subsidiary Taiho Pharmaceutical Co.,...

Amgen announced that theCommittee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis® (carfilzomib) to include treatment in combination with dexamethasone alone for adult...

Takeda Pharmaceutical Company Limited announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the current conditional approval of ADCETRIS® (brentuximab vedotin) and recommended its...

Shire plc announced that the EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the extension of the approval of Revestive®* (teduglutide) 5 mg powder and solvent for solution for injection in paediatric patients...

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and CEO at the Bernstein 32nd Annual Strategic Decisions Conference on Thursday, June 2, 2016 at 2:00 p.m. Eastern...

AbbVie will participate in the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 7:30 a.m. Central time. ...